Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 4

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 4
---
SPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise,

| ● | all                                                                                              
 references to the “Company,” “60P,” the “registrant,”                                            
 “we,” “our,” or “us” mean 60 Degrees Pharmaceuticals,                                            
 Inc., a Delaware corporation, and majority owned subsidiary 60P Australia Pty Ltd, an Australian 
 proprietary company limited by shares;                                                           |

| ● | all                                                                                   
 dollar or $ references, when used in this prospectus, refer to United States dollars. |

Except as otherwise indicated, all information in this prospectus assumes that:

| ● | no                                                                                              
 shares of common stock have been issued pursuant to any warrants, including the Common Warrants 
 and the Placement Agent Warrants.                                                               |

TRADEMARKS Solely for convenience, our trademarks and tradenames referred to in this prospectus, may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. All other trademarks, service marks and trade names included or incorporated by reference into this prospectus or the accompanying prospectus are the property of their respective owners. GLOSSARY OF SELECTED TERMS The following are definitions of certain terms that are commonly used in the medical industry and in this prospectus: “8-aminoquinoline” refers to the structural class of antimalarials to which Tafenoquine and Primaquine belong. 8-aminoquinolines are characterized by the presence of an 8-amino substitution on their core quinoline ring, which confers their unique properties including an oxidative Mode of Action and activity against the relapsing liver forms of Plasmodium vivax. “Agency of Record” refers to a marketing/advertising agency used by a Company to develop marketing collateral for a commercial pharmaceutical product. “API” means active pharmaceutical ingredient, the active molecule contained in a pharmaceutical product. ii “Arakoda” means ARAKODA ®, the 60P-owned and FDA-approved product to prevent malaria in travelers, which contains as its active pharmaceutical ingredient, Tafenoquine succinate. “Broad Spectrum of Activity” refers to a molecule or drug that is active against a range of different pathogens. “CAR-T” means chimeric antigen receptor therapy. “CLIA” means The Clinical Laboratory Improvements Amendment of 1988. “Dengue” means a mosquito-borne